(Q37809089)

23 August 2017

title

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola (English)

1 reference

23 August 2017

David Richard

2

1 reference

23 August 2017

Atli Thorarensen

3

1 reference

23 August 2017

William J. Moore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21073366

25 August 2024

language of work or name

English

0 references

publication date

14 November 2010

1 reference

full work available at URL

23 August 2017

http://www.informapharmascience.com/doi/abs/10.1517/13543776.2010.534459

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21073366

http://www.tandfonline.com/doi/pdf/10.1517/13543776.2010.534459

25 August 2024

1 reference

https://api.crossref.org/works/10.1517/13543776.2010.534459

Expert Opinion on Therapeutic Patents

25 August 2024

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1703-1722

1 reference

Rheumatoid arthritis: diagnosis and management

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

Kinase inhibitors: a new approach to rheumatoid arthritis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.534459

The Journal of Rheumatology

21 January 2018

2

35

4

Cohen SB

2007

1 reference

https://api.crossref.org/works/10.1517/13543776.2010.534459

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

25 August 2024

5

1 reference

https://api.crossref.org/works/10.1517/13543776.2010.534459

A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011

25 August 2024

8

1 reference

https://api.crossref.org/works/10.1517/13543776.2010.534459

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment

25 August 2024

9

1 reference

https://api.crossref.org/works/10.1517/13543776.2010.534459

25 August 2024

Identifiers

1 reference

23 August 2017

1 reference